New international Member MMV (Medicines for Malaria Venture) has become the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation Against Neglected Tropical Diseases.
The Pool was established in February 2009 by GSK (GlaxoSmithKline) and Alnylam Pharmaceuticals and has since been joined by MIT (Massachusetts Institute of Technology). It seeks to stimulate innovative and efficient drug discovery and development by providing public access to intellectual property (IP) and scientific know-how for neglected tropical disease research. The Pool is administered by BIO Ventures for Global Health (BVGH). The geographic focus of the pool will be the world’s Least Developed Countries as identified by the United Nations and includes much of western and central Africa as well as several countries in Southeast Asia.
Medicines for Malaria Venture, a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. Its mission is to bring public, private and philanthropic sector partners together to fund and manage the discovery, development and delivery of new medicines for the treatment and prevention of malaria in disease-endemic countries.
As contributor to the Pool, MMV will make available its IP, technology and expertise in the research and development (R&D) of antimalarial drugs to researchers developing medicines for neglected diseases.
For more information see the press release on MMV’s website.
Aug. 26, 2010
Sign up to our weekly e-newsletter for sector news, expert opinion and resources.